INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio completed the transfer of its mesenchymal stromal cell isolation process to a commercial manufacturing facility, positioning the company to generate master cell banks for its Phase 3 trial and future commercial supply. The process meets MHRA, EMA, and FDA standards, removing a key execution risk for the planned regulatory filings of Ebstrocel™ in the US, EU, and UK.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.